Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemia
ANGPTL3 inhibition represents one of the most powerful current strategies for lowering triglyceride-rich lipoproteins and residual cardiovascular risk. While monoclonal antibodies and RNA-based drugs offer effective, repeat-dose therapies, in vivo CRISPR editing could enable a one-time, lifelong correction of hypertriglyceridemia and mixed dyslipidemia. The main challenge ahead lies in ensuring safety, scalability, and equitable access if long-term efficacy and tolerability are confirmed in phase 3 trials.
Authors
- Laura Schreier (ORCID: https://orcid.org/0000-0002-6973-055X)
- Pablo Corral (ORCID: https://orcid.org/0000-0003-0017-8725)
- Natalia Nardelli (ORCID: https://orcid.org/0009-0005-4221-5813)
Institutions
- Universidad de Buenos Aires (AR)
- Instituto de Investigaciones Físicas de Mar del Plata (AR)
- Universidad Autónoma de Centro América (CR)
- Universidad Fraternidad de Agrupaciones Santo Tomás de Aquino (AR)
Publication Details
- Journal
- Current Opinion in Endocrinology Diabetes and Obesity
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1097/med.0000000000000950
- Citations
- 2
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.78